Treatment-related Complications in Childhood Acute Lymphoblastic Leukemia: Results of Medical Research Council UKALL X

Background: Acute lymphoblastic leukemia (ALL) is a heterogeneous group of lymphoid neoplasms resulting from the proliferation of malignant lymphoid cells. The aim of this study was to evaluate treatment-related complications in children with ALL receiving the Medical Research Council (MRC) UKALL X...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Middle East journal of cancer 2020-04, Vol.11 (2), p.168-173
Hauptverfasser: Ehsan Shahverdi, Pedram Karami, Farzaneh Tavakoli, Massoumeh Maki, Meysam Moazzami, Fatemeh Feizi, Peyman Salamati, Alireza Lotfipour, Mohammad Ali Ehsani
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background: Acute lymphoblastic leukemia (ALL) is a heterogeneous group of lymphoid neoplasms resulting from the proliferation of malignant lymphoid cells. The aim of this study was to evaluate treatment-related complications in children with ALL receiving the Medical Research Council (MRC) UKALL X protocol. Methods: In this retrospective cross-sectional study, children with ALL receiving the MRC UKALL X protocol from 2008 to 2015 in Bahrami University Hospital, Iran, were enrolled. The clinical and morphological features were analysed and treatment-related complications were assessed. Results: Out of 67 children with ALL receiving the MRC UKALL X protocol, 44 (65.6 %) were boys and 23 (34.4%) were girls. Seven patients (10.7%) relapsed in the three years of diagnosis, and 50 children (74.6%) had an overall survival of three years. Average age in three-year-survival group and mortality group was 6.92 (SD: 3.96) and 6.35 (SD: 7.47), respectively (P= 0.38). Conclusion: Overall survival and relapse rates in this study confirm that this protocol is an appropriate treatment strategy.
ISSN:2008-6709
2008-6687
DOI:10.30476/mejc.2019.81253.0